Cerebrovascular disease, such as presence of white matter hyperintensities (WMH), contributes to Alzheimer’s disease (AD) pathology and progression. The antihypertensive nilvadipine may reduce WMH progression by reducing amyloid-induced vasoconstriction and improving cerebral perfusion. Here we show that in patients with mild to moderate AD, nilvadipine slows the increase of WMH after 6 months, but not after 18 months, when correcting for baseline WMH. This contradicts the view that reducing blood pressure in an elderly dementia population leads to progression of white matter damage and instead seems to have a beneficial effect on WMH.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords